Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Butorphanol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 known ✓ | P41145 | 17/20 | 1.00 |
| ▸ | OPRM1 known ✓ | P35372 | 13/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 14/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butorphanol SCHEMBL20904174 | 1.00 | OPRK1 (1.00) | OPRK1OPRD1OPRM1KCNH2 | |
| Butorphanol SCHEMBL28094979 | 1.00 | OPRK1 (1.00) | OPRK1OPRD1OPRM1KCNH2 | |
| Butorphanol SCHEMBL1613498 | 1.00 | OPRK1 (1.00) | OPRK1OPRD1OPRM1KCNH2 | |
| Butorphanol SCHEMBL19427408 | 1.00 | OPRK1 (1.00) | OPRK1OPRD1OPRM1KCNH2 | |
| Butorphanol SCHEMBL27701479 | 1.00 | OPRK1 (1.00) | OPRK1OPRD1OPRM1KCNH2 | |
| Butorphanol SCHEMBL16311889 | 1.00 | OPRK1 (1.00) | OPRK1OPRD1OPRM1KCNH2 | |
| Butorphanol SCHEMBL10031253 | 1.00 | OPRK1 (1.00) | OPRK1OPRD1OPRM1KCNH2 | |
| Butorphanol SCHEMBL3749 | 1.00 | OPRK1 (1.00) | OPRK1OPRD1OPRM1KCNH2 | |
| Butorphanol SCHEMBL11529206 | 0.99 | OPRK1 (0.98) | OPRK1OPRD1OPRM1KCNH2 | |
| Butorphanol SCHEMBL2726244 | 0.99 | OPRK1 (0.98) | OPRK1OPRD1OPRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4010078-A1 | COMPOSITIONS AND METHODS OF ENHANCING OPIOID RECEPTOR ENGAGEMENT BY OPIOID HEXADIENOATES AND OPTIONALLY SUBSTITUTED HEXADIENOATES | Kappa-Pharma LLC (US) | 2022-06-15 | — | — | EP | claimed |
| US-20250213554-A1 | PROCESS OF MAKING STABLE ABUSE-DETERRENT ORAL FORMULATIONS | TRUIST BANK, A NORTH CAROLINA CHARTERED BANK | 2025-07-03 | — | — | US | disclosed |
| CN-119770423-A | Butofenol tartrate injection and preparation method thereof | 成都苑东生物制药股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| EP-3563852-B1 | BUTORPHANOL-CONTAINING PATCH | HISAMITSU PHARMACEUTICAL CO (JP) | 2025-04-02 | — | — | EP | disclosed |
| CN-119241436-A | Salt of morphinan ring compound, preparation method and application thereof | 上海医药工业研究院有限公司 | 2025-01-03 | — | — | CN | disclosed |
| EP-3909628-B1 | DEVICES FOR CONTROLLED DRUG VAPORIZATION | UNIV PRINCETON (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20240122920-A1 | PROCESS OF MAKING STABLE ABUSE-DETERRENT ORAL FORMULATIONS | COLLEGIUM PHARMACEUTICAL INC (US) | 2024-04-18 | — | — | US | disclosed |
| CN-113939277-B | Formulations and methods for drug infusion into the bladder and treatment of bladder diseases | 特瑞纲制药有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-11851439-B2 | Compositions and methods of use for opioid hexadienoates and optionally substituted hexadienoates | Kappa-Pharma LLC (US) | 2023-12-26 | — | — | US | disclosed |
| CN-117241838-A | Modified polypeptides and uses thereof | 麦考瑞大学 | 2023-12-15 | — | — | CN | disclosed |
| US-11607510-B2 | Methods and devices for controlled drug vaporization | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2023-03-21 | — | — | US | disclosed |
| CN-115697304-A | Multi-drug formulation for biodegradable subcutaneous reservoir device | 三角研究所 | 2023-02-03 | — | — | CN | disclosed |
| EP-4121111-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND FIBROTIC PULMONARY DISORDERS | University of Houston System (US) | 2023-01-25 | — | — | EP | disclosed |
| CN-110003212-B | A3 adenosine receptor agonists | 美国卫生和人力服务部 | 2022-12-06 | — | — | CN | disclosed |
| CN-110573160-B | Adhesive patch | 久光制药株式会社 | 2022-11-18 | — | — | CN | disclosed |
| CN-114685370-A | Butorphanol tartrate crystal form I and preparation method and application thereof | 成都苑东生物制药股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| CN-109970708-B | Cannabinoid receptor modulators | 艾尼纳制药公司 | 2022-06-21 | — | — | CN | disclosed |
| US-20220142918-A1 | FILM FORMULATIONS CONTAINING DEXMEDETOMIDINE AND METHODS OF PRODUCING THEM | OAKTREE FUND ADMINISTRATION, LLC | 2022-05-12 | — | — | US | disclosed |
| EP-3962522-A1 | TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES | H. Lundbeck A/S (DK) | 2022-03-09 | — | — | EP | disclosed |
| US-20220023551-A1 | METHODS AND DEVICES FOR CONTROLLED DRUG VAPORIZATION | THE TRUSTEES OF PRINCETON UNIVERSITY | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11851439-B2 | Compositions and methods of use for opioid hexadienoates and optionally substituted hexadienoates | OPRK1, OPRM1, OPRL1 | OPRK1 1/4885OPRM1 2/4885OPRD1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.